(r)-(4-((3-hydroxypyrrolidin-1-yl)methyl)phenyl)boronic acid pinacol ester
|
- $198 - $758
- Product name: (r)-(4-((3-hydroxypyrrolidin-1-yl)methyl)phenyl)boronic acid pinacol ester
- CAS: 1206641-44-2
- MF: C17H26BNO3
- MW: 303.2
- EINECS:
- MDL Number:MFCD28501980
- Synonyms:(r)-(4-((3-hydroxypyrrolidin-1-yl)methyl)phenyl)boronic acid pinacol ester;(3R)-1-{[4-(Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl}pyrrolidin-3-ol;(R)-1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-ol;3-Pyrrolidinol, 1-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]-, (3R)-;(3R)-1-{[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl}pyrrolidin-3-ol
2 prices
Selected condition:
Brand
- Chemenu
- Crysdot
Package
- 1g
- 5g
- ManufacturerChemenu
- Product numberCM205843
- Product description(R)-1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-ol 97%
- Packaging1g
- Price$198
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11332152
- Product description(R)-1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-ol 97%
- Packaging5g
- Price$758
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Chemenu | CM205843 | (R)-1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-ol 97% | 1g | $198 | 2021-12-16 | Buy |
| Crysdot | CD11332152 | (R)-1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidin-3-ol 97% | 5g | $758 | 2021-12-16 | Buy |
Properties
Boiling point :426.8±40.0 °C(Predicted)
Density :1.11±0.1 g/cm3(Predicted)
pka :14.80±0.20(Predicted)
Density :1.11±0.1 g/cm3(Predicted)
pka :14.80±0.20(Predicted)
Safety Information
| Symbol(GHS): |
|
|||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | |||||||||||||||||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
| Precautionary statements: |
|




